Key facts
- It has raised $93.9M across 3 recorded rounds; the latest was Seed Round ($3.5M) in Jan 2023.
- Notable investors include Johnson & Johnson Innovation - JLABS, Cultivation Capital, Argonautic Ventures, iSelect Fund, SeedFolio — 18 tracked in total.
- Immunophotonics has filed 5 Form Ds with the SEC since 2010, most recently Mar 2024 ($1.5M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Immunophotonics
Funding rounds
3 roundsAbout Immunophotonics
Developer of a proprietary carbohydrate polymer designed to transform tumor ablation into hypnotherapy for cancer. The company's compound is intratumorally injected after a tumor ablation, utilizing the whole repertoire of tumor-associated neoantigens available in situ for the immune system after ablation-based immunogenic cell death, inducing a systemic anti-tumor immune response, enabling clinicians to treat late-stage metastatic cancers.
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Founded
- 2008
- Employees
- 19
- Website
- immunophotonics.com/
- Ownership
- Privately Held (backing)
Immunophotonics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immunophotonics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immunophotonics in its N-PORT filings yet. We sweep new filings monthly.